Targeting CD28 and CD154 pathways, dual blockade with belatacept and dazodalibep offers potential to improve adherence in kidney transplant recipients.
Allan Kirk, MD, PhD
Advertisement
Articles by Allan Kirk, MD, PhD
Targeting CD28 and CD154 pathways, dual blockade with belatacept and dazodalibep offers a new mechanistic approach in kidney transplant care.
Advertisement